Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Eligible participants in this study are randomized 2:1 to receive either artesunate or

placebo vaginal inserts for the treatment of CIN2/3. Both groups receive three 5-day

cycles of the respective drug, at weeks 0, 2, and 4. Dosing visits can be done as

telehealth visits (medication is mailed to the patient's home). Participants are followed

after receiving artesunate at weeks 6, 17, and 40. All participants undergo a LEEP

procedure at week 17.

Primary Objective: To evaluate the histopathologic response to three 5-day cycles of

artesunate vaginal inserts in adult females with biopsy-proven HPV-associated CIN 2/3.

Secondary Objectives:

- To evaluate the safety of artesunate vaginal inserts for the treatment of CIN2/3

- To evaluate the viral clearance after three 5-day cycles of artesunate vaginal

inserts in adult females with biopsy-proven HPV-associated CIN 2/3.

- To evaluate viral clearance after three 5-day cycles of artesunate and the LEEP

procedure